Shopping Cart 0
Cart Subtotal
USD 0

Crown Bioscience Inc (6554) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Crown Bioscience Inc (Crown Bioscience) is a drug discovery company that provides drug discovery and development services. The company offers antibodies, proteins, cell lines, tumor samples, in vivo and in vitro research reagents. It offers services such as preclinical research services, oncology services, and metabolic disease services, among others. Crown Bioscience provides its preclinical research services in areas of oncology and metabolic disease. The company's oncology services comprise human surrogate trials, oncology databases, ex vivo services, in vitro services, in vivo services, translational research, preclinical formulations, and drug discovery services. Its metabolic disease services include CVMD databases, and ex vivo services. The company has its operations in the US, China, the UK, and Taiwan. Crown Bioscience is headquartered in Taipei, Taiwan.

Crown Bioscience Inc (6554)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Crown Bioscience Acquires PDX Business Unit from Molecular Response 13

Venture Financing 14

CBT Pharma Raises USD5 Million in Seed Financing 14

Crown Bioscience Raises Funds in Venture Financing 15

Crown Bioscience Raises USD27 Million in Series D Financing 16

Partnerships 17

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 17

Crown Bioscience Enters into Partnership with Glycotope 18

Crown Bioscience Enters into Partnership with Phanes Therapeutics 19

Crown Bioscience Enters into Co-Development Agreement with Data Sciences International 20

Crown Bioscience and Jackson Lab Enter into Agreement 21

Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 22

Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 23

Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 24

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 25

Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 26

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 27

Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 28

Licensing Agreements 29

Crown Bioscience Enters into Licensing Agreement with University of Utah 29

Crown Bioscience Enters into Licensing Agreement with Shanghai Model Organisms 30

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 31

Crown Bioscience Enters into Licensing Agreement with University of York 32

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 33

Equity Offering 34

Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 34

Crown Bioscience Raises Funds through IPO 35

Acquisition 36

JSR Acquires Crown Bioscience for USD399.7 Million 36

Crown Bioscience Acquires PreClinOmics 38

Crown Bioscience Acquires Preclinical Oncology Services 39

Crown Bioscience Inc-Key Competitors 40

Crown Bioscience Inc-Key Employees 41

Crown Bioscience Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Strategy And Business Planning 43

Jul 13, 2017: Crown Bioscience Expands its Life Science Portfolio 43

Jan 26, 2017: CrownBio Announces Expansion of Life Science Division 44

Jan 24, 2017: Crown Bioscience Announces Expansion of Therapeutic Expertise into Inflammation 45

Jan 12, 2017: Crown Bioscience Expands US Capacity for Cardiovascular & Metabolic Disease Research; Partners with New Iberia Research Center of Louisiana 46

Financial Announcements 47

Aug 10, 2017: Crown Bioscience Announces Second Quarter Results 47

May 19, 2017: Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results 48

Corporate Communications 49

Nov 09, 2017: Crown Bioscience Announcing the 2017 Board of Directors Election Results Dr. Guoliang Yu re-elected as the Chairman 49

Sep 27, 2017: Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role 50

Aug 10, 2017: Crown Bioscience Appoints Dr. Yangzhou Wang as Sr. VP of Global Operations 51

Government and Public Interest 52

Jul 19, 2018: Crownbio supports excellence in translational research with grant award that funds innovative PDX model development in immuno-oncology 52

Nov 17, 2017: CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research 53

Product News 54

Nov 23, 2017: Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring 54

Oct 10, 2017: CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes 55

Sep 13, 2017: CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer 56

Aug 01, 2017: CrownBio Launches Innovative Inflammatory Disease Models to Advance Pre-Clinical Research 57

Other Significant Developments 58

Sep 26, 2018: CrownBio completes validation of prostate cancer patient-derived xenograft (PDX) models 58

Jul 27, 2018: CrownBio Expands Novel Humanized Models for Targeted Immunotherapy Development to San Diego, CA Research Center 59

Feb 20, 2018: Crown Bioscience: CAR T-Cell Therapy Platform 60

Feb 09, 2018: Enhanced MuScreen Platform Revolutionizes Preclinical Development of Immunotherapeutics 61

Jan 09, 2018: Crown Bioscience Launches CrownSyn, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies 62

Apr 19, 2017: Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products 63

Mar 09, 2017: Crown Bioscience Enables Secure Data Real Time Access with the Release of Client Facing Portal 64

Feb 16, 2017: Crown Bioscience Enhances Digital Connectivity with the Release of OncoExpress Technology Platform 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Crown Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Crown Bioscience Acquires PDX Business Unit from Molecular Response 13

CBT Pharma Raises USD5 Million in Seed Financing 14

Crown Bioscience Raises Funds in Venture Financing 15

Crown Bioscience Raises USD27 Million in Series D Financing 16

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 17

Crown Bioscience Enters into Partnership with Glycotope 18

Crown Bioscience Enters into Partnership with Phanes Therapeutics 19

Crown Bioscience Enters into Co-Development Agreement with Data Sciences International 20

Crown Bioscience and Jackson Lab Enter into Agreement 21

Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 22

Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 23

Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 24

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 25

Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 26

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 27

Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 28

Crown Bioscience Enters into Licensing Agreement with University of Utah 29

Crown Bioscience Enters into Licensing Agreement with Shanghai Model Organisms 30

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 31

Crown Bioscience Enters into Licensing Agreement with University of York 32

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 33

Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 34

Crown Bioscience Raises Funds through IPO 35

JSR Acquires Crown Bioscience for USD399.7 Million 36

Crown Bioscience Acquires PreClinOmics 38

Crown Bioscience Acquires Preclinical Oncology Services 39

Crown Bioscience Inc, Key Competitors 40

Crown Bioscience Inc, Key Employees 41

Crown Bioscience Inc, Other Locations 42

Crown Bioscience Inc, Subsidiaries 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Crown Bioscience Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Crown Bioscience Inc (Crown Bioscience) is a drug discovery company that provides drug discovery and development services. The company offers antibodies, proteins, cell lines, tumor samples, in vivo and in vitro research reagents. It offers services such as preclinical research services, oncology services, and metabolic disease services, among others. Crown Bioscience provides its preclinical research services in areas of oncology and metabolic disease. The company's oncology services comprise human surrogate trials, oncology databases, ex vivo services, in vitro services, in vivo services, translational research, preclinical formulations, and drug discovery services. Its metabolic disease services include CVMD databases, and ex vivo services. The company has its operations in the US, China, the UK, and Taiwan. Crown Bioscience is headquartered in Taipei, Taiwan.

Crown Bioscience Inc (6554)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Crown Bioscience Acquires PDX Business Unit from Molecular Response 13

Venture Financing 14

CBT Pharma Raises USD5 Million in Seed Financing 14

Crown Bioscience Raises Funds in Venture Financing 15

Crown Bioscience Raises USD27 Million in Series D Financing 16

Partnerships 17

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 17

Crown Bioscience Enters into Partnership with Glycotope 18

Crown Bioscience Enters into Partnership with Phanes Therapeutics 19

Crown Bioscience Enters into Co-Development Agreement with Data Sciences International 20

Crown Bioscience and Jackson Lab Enter into Agreement 21

Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 22

Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 23

Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 24

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 25

Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 26

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 27

Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 28

Licensing Agreements 29

Crown Bioscience Enters into Licensing Agreement with University of Utah 29

Crown Bioscience Enters into Licensing Agreement with Shanghai Model Organisms 30

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 31

Crown Bioscience Enters into Licensing Agreement with University of York 32

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 33

Equity Offering 34

Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 34

Crown Bioscience Raises Funds through IPO 35

Acquisition 36

JSR Acquires Crown Bioscience for USD399.7 Million 36

Crown Bioscience Acquires PreClinOmics 38

Crown Bioscience Acquires Preclinical Oncology Services 39

Crown Bioscience Inc-Key Competitors 40

Crown Bioscience Inc-Key Employees 41

Crown Bioscience Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Strategy And Business Planning 43

Jul 13, 2017: Crown Bioscience Expands its Life Science Portfolio 43

Jan 26, 2017: CrownBio Announces Expansion of Life Science Division 44

Jan 24, 2017: Crown Bioscience Announces Expansion of Therapeutic Expertise into Inflammation 45

Jan 12, 2017: Crown Bioscience Expands US Capacity for Cardiovascular & Metabolic Disease Research; Partners with New Iberia Research Center of Louisiana 46

Financial Announcements 47

Aug 10, 2017: Crown Bioscience Announces Second Quarter Results 47

May 19, 2017: Crown Bioscience Announces Record Breaking Growth With First 2017 Quarter Results 48

Corporate Communications 49

Nov 09, 2017: Crown Bioscience Announcing the 2017 Board of Directors Election Results Dr. Guoliang Yu re-elected as the Chairman 49

Sep 27, 2017: Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role 50

Aug 10, 2017: Crown Bioscience Appoints Dr. Yangzhou Wang as Sr. VP of Global Operations 51

Government and Public Interest 52

Jul 19, 2018: Crownbio supports excellence in translational research with grant award that funds innovative PDX model development in immuno-oncology 52

Nov 17, 2017: CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research 53

Product News 54

Nov 23, 2017: Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring 54

Oct 10, 2017: CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes 55

Sep 13, 2017: CrownBio's Integrated Oncology Platform Helps Advance Apogenix's Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer 56

Aug 01, 2017: CrownBio Launches Innovative Inflammatory Disease Models to Advance Pre-Clinical Research 57

Other Significant Developments 58

Sep 26, 2018: CrownBio completes validation of prostate cancer patient-derived xenograft (PDX) models 58

Jul 27, 2018: CrownBio Expands Novel Humanized Models for Targeted Immunotherapy Development to San Diego, CA Research Center 59

Feb 20, 2018: Crown Bioscience: CAR T-Cell Therapy Platform 60

Feb 09, 2018: Enhanced MuScreen Platform Revolutionizes Preclinical Development of Immunotherapeutics 61

Jan 09, 2018: Crown Bioscience Launches CrownSyn, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies 62

Apr 19, 2017: Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products 63

Mar 09, 2017: Crown Bioscience Enables Secure Data Real Time Access with the Release of Client Facing Portal 64

Feb 16, 2017: Crown Bioscience Enhances Digital Connectivity with the Release of OncoExpress Technology Platform 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Crown Bioscience Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Crown Bioscience Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Crown Bioscience Inc, Medical Devices Deals, 2012 to YTD 2018 10

Crown Bioscience Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Crown Bioscience Acquires PDX Business Unit from Molecular Response 13

CBT Pharma Raises USD5 Million in Seed Financing 14

Crown Bioscience Raises Funds in Venture Financing 15

Crown Bioscience Raises USD27 Million in Series D Financing 16

Crown Bioscience Enters into Partnership Agreement with Pierre Fabre Research Institute 17

Crown Bioscience Enters into Partnership with Glycotope 18

Crown Bioscience Enters into Partnership with Phanes Therapeutics 19

Crown Bioscience Enters into Co-Development Agreement with Data Sciences International 20

Crown Bioscience and Jackson Lab Enter into Agreement 21

Crown Bioscience Enters into Agreement with Jiangsu Qyun Bio-Pharma 22

Crown Bioscience Expands Co-Development Agreement with NRCMM for Novel Immuno-oncology Mouse Models 23

Crown Bioscience Enters into Co-Development Agreement with NRCMM for New Cancer Models 24

Crown Bioscience Enters Into Agreement With Horizon Discovery To Develop In Vivo Models For Drug Discovery 25

Crown Bioscience Enters Into Agreement With Beijing Purunao To Develop Cancer Drugs 26

Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 27

Crown Bioscience Enters Into Co-Development With Jiangsu Hengrui Medicine 28

Crown Bioscience Enters into Licensing Agreement with University of Utah 29

Crown Bioscience Enters into Licensing Agreement with Shanghai Model Organisms 30

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 31

Crown Bioscience Enters into Licensing Agreement with University of York 32

CBT Pharma Enters into Licensing Agreement with Crown Bioscience 33

Crown Bioscience Raises USD20.8 Million in Public Offering of Shares 34

Crown Bioscience Raises Funds through IPO 35

JSR Acquires Crown Bioscience for USD399.7 Million 36

Crown Bioscience Acquires PreClinOmics 38

Crown Bioscience Acquires Preclinical Oncology Services 39

Crown Bioscience Inc, Key Competitors 40

Crown Bioscience Inc, Key Employees 41

Crown Bioscience Inc, Other Locations 42

Crown Bioscience Inc, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Crown Bioscience Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.